Brain Imaging: Cocaine Effects & Medication Development - 5 - Tabular View

Tracking Information

First Received Date ^ICMJE

September 20, 1999

Last Updated Date

August 16, 2005

Start Date ^ICMJE

May 1995

Primary Completion Date

Current Primary Outcome Measures ^ICMJE

Absolute change in rCBF at 5 & 15 minutes (Xe)
Relative change in rCBF at 5, 19, & 33 minutes (O15)
Correlated with a) subjective effects, b) venous blood level of coca, c) autonomic variables

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT00000270 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Original Secondary Outcome Measures ^ICMJE

Descriptive Information

Brief Title ^ICMJE

Brain Imaging: Cocaine Effects & Medication Development - 5

Official Title ^ICMJE

Brain Imaging: Cocaine Effects & Medication Development

Brief Summary

The purpose of this study is to define temporal profile of brain activation (rCBF) using Xenon-SPECT and O 15-PET.

Detailed Description

Study Phase

Phase IV

Study Type ^ICMJE

Interventional

Study Design ^ICMJE

Treatment

Condition ^ICMJE

Cocaine-Related Disorders

Intervention ^ICMJE

Drug: Cocaine

Study Arms / Comparison Groups

Publications *

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Completion Date

Primary Completion Date

Eligibility Criteria ^ICMJE

Please contact site for information.

Gender

Both

Ages

18 Years to 48 Years

Accepts Healthy Volunteers

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT ID ^ICMJE

NCT00000270

Responsible Party

Study ID Numbers ^ICMJE

NIDA-09236-5, P50-09236-5

Study Sponsor ^ICMJE

National Institute on Drug Abuse (NIDA)

Collaborators ^ICMJE

New York State Psychiatric Institute

Investigators ^ICMJE

Principal Investigator:

Herbert Kleber, M.D.

New York State Psychiatric Institute

Information Provided By

National Institute on Drug Abuse (NIDA)

Verification Date

May 1996

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP